Interestingly, patients with prolymphocytic leukemia-like MCL with MYC amplification, no expression of CD38, and loss of TP53 showed prolonged survival outcomes similar to those with indolent leukemic MCL. This evidence concerns the gene TP53 and mantle cell lymphoma.